hVIVO (LON:HVO) Trading Up 14.9% – Here’s Why

hVIVO plc (LON:HVO)’s share price was up 14.9% during trading on Monday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 10 ($0.13). Approximately 45,640,137 shares changed hands during trading, an increase of 1,091% from the average daily volume of 3,830,527 shares. The stock had previously closed at GBX 8.70 ($0.12).

Analyst Ratings Changes

Separately, Shore Capital reissued a “buy” rating on shares of hVIVO in a report on Friday.

hVIVO Stock Performance

The stock has a market cap of £75.71 million, a PE ratio of 4.41 and a beta of 0.97. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The stock has a 50-day moving average of GBX 16.16 and a 200 day moving average of GBX 18.04.

hVIVO (LON:HVO) last announced its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Equities analysts predict that hVIVO plc will post 1.5492958 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Yamin Mo’ Khan sold 3,062,246 shares of the business’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($700,648.48). 14.03% of the stock is owned by insiders.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.